CD274 and neoplasm: Of note, in the KEYNOTE 010 study [11], the magnitude of benefit with pembrolizumab correlated with PD-L1 expression, with increased benefit seen in patients with tumors with strong PD-L1 expression, defined as expression on at least 50% of tumor cells, regardless of the staining intensity with the 22C3 clone [11].